This disclosure relates to reagents such as antisense oligonucleotides that bind to nucleic acids encoding cryptic exons, thereby inhibiting or preventing ELAVL3 cryptic splicing, and to their use in the treatment or prevention of TDP-43-related neurodegenerative or neurological diseases or conditions associated therewith. In some embodiments, the antisense oligonucleotide is a nucleobasepolymer capable of reducing the level or expression of intracellular ELAVL3 cryptic exonRNA and increasing or restoring the expression of functional ELAVL3 protein without substantially incorporating the cryptic exonRNApeptide sequence.